PainReform Ltd
PRFX
Get informed when a big investor buys or sells
+ FollowMarket Cap$108.72K
Close$
$6.42
405.2% upside
Current Fair Value
405.2% upsideUndervalued by 405.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $108,718.00 |
|---|---|
| Enterprise Value | $-2,995,282.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-7.47 |
| Beta | 1.05 |
| Outstanding Shares | 871,238 |
Return
| Return on Equity | -56.63% |
|---|---|
| Return on Assets | -40.32% |
| Return on Invested Capital | -53.59% |
Valuation & Multiples
| P/E Ratio | -0.04 |
|---|---|
| PEG | -0.1 |
| Price to Sales | - |
| Price to Book Ratio | 0.13 |
| Enterprise Value to Revenue | -176.19 |
| Enterprise Value to EBIT | 0.58 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.01 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 2, 2026
EPS Estimate
$-612.00
Average shareholder expectationRevenue Estimate
$7,361
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.43%▲ 2.43% |
|---|---|
| Total Invested | $31,939 |
| Investors Holding | 4▲ 4.00% |
ESG Score
No data
About PainReform Ltd
2 employeesPainReform is a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics. PRF-110, the Company's lead product, is based on the local anesthetic ropivacaine, targeting the post-operative pai...